Håndtering af hjertekomplikationer sekundært til medicinsk kræftbehandling

Ann Banke; Anne Polk; Dorte Nielsen; Lars Videbæk; Ulrik Overgaard; Emil Loldrup Fosbøl; Merete Vaage-Nielsen; Kirsten Melgaard Nielsen; Morten Schou

Håndtering af hjertekomplikationer sekundært til medicinsk kræftbehandling

Translated title of the contribution: Management of cardiovascular complications secondary to medical treatment of cancer

Ann Banke, Anne Polk, Dorte Nielsen, Lars Videbæk, Ulrik Overgaard, Emil Loldrup Fosbøl, Merete Vaage-Nielsen, Kirsten Melgaard Nielsen, Morten Schou

Abstract

As the prognoses of both heart and cancer patients have improved along with a longer life expectancy in the general population, the prevalence of both heart- and cancer diseases is increasing. Thus, a larger proportion of cancer patients will have cardiovascular co-morbidity and an increased risk of cardiovascular complications during and after cancer treatment. In this article, the current knowledge on the prevention, monitoring and treatment of cardiotoxicity induced by medical anti-cancer treatment with focus on anthracyclines, trastuzumab and 5-fluorouracil is described.

Translated title of the contribution	Management of cardiovascular complications secondary to medical treatment of cancer
Original language	Danish
Article number	V04170269
Journal	Ugeskrift for Laeger
Volume	180
Issue number	7
Number of pages	5
ISSN	0041-5782
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://ugeskriftet.dk/videnskab/haandtering-af-hjertekomplikationer-sekundaert-til-medicinsk-kraeftbehandling

Cite this

@article{b1995198e60e46aa84529f1826373054,

title = "H{\aa}ndtering af hjertekomplikationer sekund{\ae}rt til medicinsk kr{\ae}ftbehandling",

abstract = "As the prognoses of both heart and cancer patients have improved along with a longer life expectancy in the general population, the prevalence of both heart- and cancer diseases is increasing. Thus, a larger proportion of cancer patients will have cardiovascular co-morbidity and an increased risk of cardiovascular complications during and after cancer treatment. In this article, the current knowledge on the prevention, monitoring and treatment of cardiotoxicity induced by medical anti-cancer treatment with focus on anthracyclines, trastuzumab and 5-fluorouracil is described.",

keywords = "Anthracyclines/adverse effects, Antineoplastic Agents/adverse effects, Biomarkers/analysis, Cardiotoxicity/diagnosis, Echocardiography, Electrocardiography, Fluorouracil/adverse effects, Heart Diseases/chemically induced, Humans, Monitoring, Physiologic, Neoplasms/drug therapy, Risk Factors, Trastuzumab/adverse effects",

author = "Ann Banke and Anne Polk and Dorte Nielsen and Lars Videb{\ae}k and Ulrik Overgaard and Fosb{\o}l, {Emil Loldrup} and Merete Vaage-Nielsen and Nielsen, {Kirsten Melgaard} and Morten Schou",

year = "2018",

language = "Dansk",

volume = "180",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "7",

}

TY - JOUR

T1 - Håndtering af hjertekomplikationer sekundært til medicinsk kræftbehandling

AU - Banke, Ann

AU - Polk, Anne

AU - Nielsen, Dorte

AU - Videbæk, Lars

AU - Overgaard, Ulrik

AU - Fosbøl, Emil Loldrup

AU - Vaage-Nielsen, Merete

AU - Nielsen, Kirsten Melgaard

AU - Schou, Morten

PY - 2018

Y1 - 2018

N2 - As the prognoses of both heart and cancer patients have improved along with a longer life expectancy in the general population, the prevalence of both heart- and cancer diseases is increasing. Thus, a larger proportion of cancer patients will have cardiovascular co-morbidity and an increased risk of cardiovascular complications during and after cancer treatment. In this article, the current knowledge on the prevention, monitoring and treatment of cardiotoxicity induced by medical anti-cancer treatment with focus on anthracyclines, trastuzumab and 5-fluorouracil is described.

AB - As the prognoses of both heart and cancer patients have improved along with a longer life expectancy in the general population, the prevalence of both heart- and cancer diseases is increasing. Thus, a larger proportion of cancer patients will have cardiovascular co-morbidity and an increased risk of cardiovascular complications during and after cancer treatment. In this article, the current knowledge on the prevention, monitoring and treatment of cardiotoxicity induced by medical anti-cancer treatment with focus on anthracyclines, trastuzumab and 5-fluorouracil is described.

KW - Anthracyclines/adverse effects

KW - Antineoplastic Agents/adverse effects

KW - Biomarkers/analysis

KW - Cardiotoxicity/diagnosis

KW - Echocardiography

KW - Electrocardiography

KW - Fluorouracil/adverse effects

KW - Heart Diseases/chemically induced

KW - Humans

KW - Monitoring, Physiologic

KW - Neoplasms/drug therapy

KW - Risk Factors

KW - Trastuzumab/adverse effects

M3 - Tidsskriftartikel

C2 - 29465031

SN - 0041-5782

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 7

M1 - V04170269

ER -

Håndtering af hjertekomplikationer sekundært til medicinsk kræftbehandling

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this